The stock's fall snapped a three-day winning streak.

AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

CHENNAI: Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in Indian pharma/biotech innova ...

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate (ACM-001.1) ...

Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data ...

Total aggregate value of the drugs generating the highest sales in 2024 rose 6.5% vs. 2023, and jumped 53% over five years.

Eli Lilly’s blockbuster GLP-1 drugs dominate headlines, but its broader portfolio deserves a standing ovation for driving ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune ...

AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the ...